No Data
CARsgen Therapeutics Presents Results of 3 Drugs at US Hematology Meet
The U.S. bioterrorism law has undergone significant changes, the CRO concept has launched a major counterattack, and WuXi AppTec is excited!
Industry pessimistic expectations may improve.
How to break through the challenges in the development of innovative drugs? The industry suggests focusing on internationalization.
① The year 2024 will be the inaugural year of large-scale authorized trade, and going abroad has become an important direction for the development of local pharmaceutical companies; ② Chinese企业品牌, clinical trial capabilities, data presentation formats, and levels of international operation still need time and practical verification.
Hong Kong stock movement | Kexing Pharmaceutical-B (02171) rises over 5%. Data on SGKZ, CT071, and CT0590 will be presented at the 2024 ASH annual meeting.
China Traditional Chinese Medicine Group Co., Ltd. - B (02171) rose more than 5%, as of the time of publication, it rose by 5.75%, to 6.8 Hong Kong dollars, with a turnover of 32.7907 million Hong Kong dollars.
National medical insurance drug list unveiling soon! Keji Pharmaceutical's stock surged over 9%, leading the way in Hong Kong pharmaceutical stocks.
1. What is the importance of centralized procurement of pharmaceutical companies by medical insurance? 2. Which areas of products are expected to be included in the 2024 National Medical Insurance Drug Catalog?
Insiders Of CARsgen Therapeutics Holdings Are Up 18% On Their CN¥12.7m Purchase
Insiders Could Have Profited By Holding Onto CARsgen Therapeutics Holdings Shares Despite 23% Drop
No Data
